Klinger M - Search Results

1

Reccurence of Kaposi's sarcoma after increased exposure to sirolimus.

Boratyńska M, Zmonarski SC, Klinger M. Boratyńska M, et al. Among authors: klinger m. Int Immunopharmacol. 2006 Dec 20;6(13-14):2018-22. doi: 10.1016/j.intimp.2006.09.018. Epub 2006 Oct 18. Int Immunopharmacol. 2006. PMID: 17161356

2

Conversion from cyclosporine-based immunosuppression to tacrolimus/mycophenolate mofetil in patients with refractory and ongoing acute renal allograft rejection.

Boratyńska M, Banasik M, Patrzałek D, Klinger M. Boratyńska M, et al. Among authors: klinger m. Ann Transplant. 2006;11(2):51-6. Ann Transplant. 2006. PMID: 17494290 Review.

3

Impact of sirolimus treatment in kidney allograft recipients with prolonged cold ischemia times: 5-year outcomes.

Boratynska M, Banasik M, Patrzalek D, Klinger M. Boratynska M, et al. Among authors: klinger m. Exp Clin Transplant. 2008 Mar;6(1):59-66. Exp Clin Transplant. 2008. PMID: 18405247 Free article.

4

Kaposi's sarcoma in renal transplant recipients.

Zmonarski SC, Boratyńska M, Puziewicz-Zmonarska A, Kazimierczak K, Klinger M. Zmonarski SC, et al. Among authors: klinger m. Ann Transplant. 2005;10(2):59-65. Ann Transplant. 2005. PMID: 16218035 Review.

5

Mycophenolate mofetil severely depresses antibody response to CMV infection in early posttransplant period.

Zmonarski SC, Boratynska M, Madziarska K, Klinger M, Kusztel M, Patrzalek D, Szyber P. Zmonarski SC, et al. Among authors: klinger m. Transplant Proc. 2003 Sep;35(6):2205-6. doi: 10.1016/s0041-1345(03)00764-4. Transplant Proc. 2003. PMID: 14529889

6

Sirolimus delays recovery from posttransplant renal failure in kidney graft recipients.

Boratyńska M, Banasik M, Patrzalek D, Szyber P, Klinger M. Boratyńska M, et al. Among authors: klinger m. Transplant Proc. 2005 Mar;37(2):839-42. doi: 10.1016/j.transproceed.2004.12.010. Transplant Proc. 2005. PMID: 15848550

7

Regression of Kaposi's sarcoma in renal graft recipients after conversion to sirolimus treatment.

Zmonarski SC, Boratyńska M, Rabczyński J, Kazimierczak K, Klinger M. Zmonarski SC, et al. Among authors: klinger m. Transplant Proc. 2005 Mar;37(2):964-6. doi: 10.1016/j.transproceed.2004.12.172. Transplant Proc. 2005. PMID: 15848592

8

Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies.

Boratyńska M, Watorek E, Smolska D, Patrzałek D, Klinger M. Boratyńska M, et al. Among authors: klinger m. Transplant Proc. 2007 Nov;39(9):2736-9. doi: 10.1016/j.transproceed.2007.08.078. Transplant Proc. 2007. PMID: 18021973

9

[Mycophenolic acid concentration profiles may select recipients with high-risk of acute rejection in renal transplant recipients].

Kuriata-Kordek M, Boratyńska M, Urbaniak J, Woźniak M, Patrzałek D, Szyber P, Klinger M. Kuriata-Kordek M, et al. Among authors: klinger m. Pol Merkur Lekarski. 2006 Aug;21(122):161-3; discussion 164. Pol Merkur Lekarski. 2006. PMID: 17144102 Polish.

10

Malignancy after renal transplantation in the new era of immunosuppression.

Watorek E, Boratynska M, Smolska D, Patrzalek D, Klinger M. Watorek E, et al. Among authors: klinger m. Ann Transplant. 2011 Apr-Jun;16(2):14-8. Ann Transplant. 2011. PMID: 21716180

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

900 results

Search Page

Filters